Lisa M. Nijm, MD, JD​

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

Understanding nuances of reimbursement for novel, sustained-release ophthalmic drugs can help maximize the opportunity for patients and practice.

Amid a surge in dry eye cases since reopening her practice during the ongoing pandemic, Lisa Nijm, MD, JD, shares how cyclosporine, a well-established form of treatment, poses both challenges and advantages for ophthalmologists.